Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07467707) titled 'A Phase 3B Trial of the CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults' on March 9.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Bavarian Nordic
Condition:
Chikungunya Virus
Intervention:
Biological: CHIKV VLP vaccine
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: May 2026
Target Sample Size: 6144
Countries of Recruitment:
Philippines
Thailand
Phili...